Good Therapeutics is a discovery-stage biotechnology company that is developing protein-based drugs with regulated, context-dependent activity.
Investors 2
Funding Rounds 3
| Date | Series | Amount | Investors |
| 30.12.2021 | Series B | $8M | - |
| 21.05.2020 | - | $11M | - |
| 19.02.2019 | - | $11M | - |
Mentions in press and media 6
| Date | Title | Description |
| 07.09.2022 | Roche shells out $250M to acquire Good Therapeutics and its preclinical oncology program | Roche announced Wednesday that it is paying $250 million in cash to acquire Good Therapeutics, a Seattle-based preclinical biotech company.
Good has raised a little over $30 million since it was founded in 2016. The company is focused on cy... |
| 07.09.2022 | Roche to acquire Good Therapeutics’ lead drug program for $250M, plus milestone payments | Seattle-based Good Therapeutics designs therapies that can be administered systemically for targeted activation in the body. (Good Therapeutics Graphic)
Pharmaceutical giant Roche will acquire Good Therapeutics, reeling in its lead program ... |
| 30.12.2021 | Good Therapeutics Lands $8M Series B Funding |
SEATTLE, WA, Good Therapeutics has raised an $8 million Series B financing round.
>> Click here for more funding data on Good Therapeutics
>> To export Good Therapeutics funding data to PDF and Excel, click here
Investors... |
| 30.12.2021 | Good Therapeutics lands $8M to develop protein drugs that work only where needed in the body | Good Therapeutics CEO John Mulligan. (Good Therapeutics Photo)
The news: Seattle startup Good Therapeutics has raised $8 million to advance its therapeutic proteins designed to operate only where they are needed in the body.
The platform: T... |
| 21.05.2020 | Good Therapeutics raises $11M to develop ‘context dependent’ protein drugs | Good Therapeutics CEO John Mulligan. (Good Therapeutics Photo)
Seattle biotech startup Good Therapeutics raised another $11 million to create “context dependent” protein drugs that act only when needed.
The 4-year-old company is developing ... |
| 19.02.2019 | Seattle biotech startup Good Therapeutics raises $11M to make smart cancer therapies | Good Therapeutics, a new Seattle biotech startup that aims to develop protein drugs that act only when needed, raised $11 million in an equity round, according to a new SEC filing.
The secretive startup is trying to “make safer, more effect... |
Reviews 0
